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Patients undergoing long-term therapy for PD often experience motor ﬂuctuations and nocturnal disturbances. In a post-hoc
analysis, we explored eﬀects of ropinirole prolonged release on sleep, night-time awakenings, and “on” time over 24 hours.
Patients with advanced PD suboptimally controlled with L-dopa were randomized to adjunctive ropinirole prolonged release
(2–24mg/day) or placebo for 24 weeks. Awake/asleep and, if awake, “on”/“oﬀ” status was recorded via diary cards. At week
24 last observation carried forward, changes in nighttime or daytime sleep duration were not signiﬁcantly diﬀerent between
treatments. Of patients with baseline awakenings, a signiﬁcantly higher proportion in the ropinirole prolonged release group
had a reduction in awakenings versus placebo. Patients receiving ropinirole prolonged release had a signiﬁcantly greater increase
in amount/percentage of awake time “on”/“on” without troublesome dyskinesia during all periods assessed (including night-time
and early morning), versus placebo, and higher odds for being “on” on waking. Adjunctive once-daily ropinirole prolonged release
may help provide 24-hour symptom control in patients with advanced PD not optimally controlled with L-dopa.
1.Introduction
Patients undergoing long-term therapy for Parkinson’s dis-
ease (PD) often experience motor ﬂuctuations, of which
“wearing oﬀ” is the ﬁrst and most frequent complication.
This is characterized by impairment of motor control
between doses, resulting in periods when symptoms includ-
ing bradykinesia, rigidity, and tremor are not optimally
controlled. A major aim in the management of advanced PD
is to decrease motor ﬂuctuations, time spent “oﬀ”o r“ o n ”
with troublesome dyskinesia.
Patients with PD also often suﬀer from nocturnal
disturbances reﬂected by motor and nonmotor symptoms.
Community-based studies report a 60% prevalence of sleep
disorders in patients with PD, compared with 33% in healthy
matched controls [1, 2]. Insomnia, restless legs syndrome,
motor symptoms, pain, nocturia, urinary incontinence,
and neuropsychiatric problems are causes of nocturnal
sleep disturbances [3] .I nas t u d yu s i n gas e l f - c o m p l e t e d
questionnaire, insomnia was reported by 46% of patients,
restless legs by 42%, acting out during dreams by 36%,
intense/vivid dreams by 34%, and daytime sleepiness by 31%
of patients [4]. As a consequence of sleep disorders, patients’
quality of life may be seriously impaired [5, 6], but this is
frequently overlooked in clinical settings [7, 8].
Althoughtreatmentwithdopamineagonistscanalleviate
some sleep problems in PD [9], it is thought to be one of
the factors contributing to increased daytime sleepiness and
sudden onset of sleep [10–12]; preliminary evidence suggests
that it may also contribute to sleep fragmentation or night
awakenings [13, 14]. Early morning symptoms of PD may2 Parkinson’s Disease
be more likely to occur if the eﬀects of the previous dose of
dopaminergic medication wear oﬀ.
Theprolonged-releaseformulationofthedopamineago-
nist ropinirole provides patients with continuous ropinirole
delivery and fewer ﬂuctuations in plasma levels over 24
hours compared with the immediate-release formulation
[15]. Once-daily ropinirole prolonged release is an eﬀective
adjunctive therapy in the treatment of PD and has been
shown to have beneﬁcial eﬀects on theamount (and percent-
age) of awake time spent “on” and awake time spent “on”
without troublesome dyskinesia [16], as well as on nocturnal
symptoms (measured by the Parkinson’s Disease Sleep Scale
[PDSS]) [16].
Previous analyses of the diary card data collected during
EASE-PD Adjunct explored the 24-hour period as a whole
to provide total “on”/“oﬀ”t i m e s[ 16]. In the current post-
hoc diary card analyses, the 24-hour period was subdivided
in order to assess patients’ status during speciﬁc periods of
thedayandnight.Theseanalyseswereundertakentoexplore
in more detail the eﬀects of adjunctive ropinirole prolonged
release on sleep duration and nighttime awakenings, and to
gain better understanding of continued eﬀects over 24 hours
by examining “on” time, and “on” time without troublesome
dyskinesia, during diﬀerent periods of the day/night, and the
probability of being “on” on waking in the morning.
2. Methods
2.1. Study Design and Patients. EASE-PD Adjunct
(101468/169; NCT00381472) was a Phase III, randomized,
double-blind, parallel-group, placebo-controlled, 24-week,
multicentre study that has been described elsewhere [16].
Patients were included if they were aged 30 years or
older, had idiopathic PD (Hoehn & Yahr stage II–IV) not
optimally controlled with L-dopa, had been maintained on
a stable dose of L-dopa for at least 4 weeks with suboptimal
control of symptoms, and had spent at least 3hours/day
awake time “oﬀ” during the baseline period. Exclusion
criteria included: incapacitating dyskinesia, any dopamine
agonistusewithin4weeksofscreening,signiﬁcantoruncon-
trolled psychiatric, neurological or other medical disorders,
dementia, drug abuse or alcoholism. All patients provided
written informed consent approved by their respective ethics
committee or institutional review board. The study was
conducted in accordance with good clinical practice, patient
conﬁdentiality requirements, and the guiding principles of
the Declaration of Helsinki.
2.2. Treatment. Patients were randomized (1:1), using a
computerized schedule, to 24 weeks of treatment with
adjunctive ropinirole prolonged release or placebo, concur-
rent with their pre-existing L-dopa treatment. To ensure
blinding, the titration schedule referred to numbered dosage
levels of study medication, both groups were dosed similarly,
and ropinirole prolonged release and placebo tablets were
identical in appearance and packaging. Titration and adjust-
ment of both study medication and L-dopa were based on
the individual clinician’s judgment.
The starting dose of study medication was 2mg/day, and
doses were to be titrated to the optimal therapeutic dose, up
to a maximum of 24mg/day. When a dose of 8mg/day of
study medication was reached, the dose of L-dopa was to be
reduced and reduced again with each subsequent increase in
study medication. If symptom control was lost, the dose of
study medication was to be increased to the next dose level.
If symptoms did not improve after two up-titrations of study
medication, the L-dopa dose could be increased up to (but
not above) the baseline dose.
Selegiline,amantadine,anticholinergics,andcatechol-O-
methyl-transferase inhibitors were permitted, provided the
dose was stable for at least 4 weeks prior to screening and
remained stable during the study.
2.3. Assessments. Patients were evaluated at baseline and
weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24. Diary
cards (Figure 1) were used to record whether patients were
awake or asleep, and whether they were “on” or “oﬀ”( i f
awake), and, if “on”, whether they experienced troublesome
dyskinesia for each 0.5-hour period during two 24-hour
periods. Patients were asked to complete two 24-hour diary
cards prior to each postbaseline study visit. During the 2
weeks of the placebo run-in period, patients were asked to
complete two 24-hour diary cards during each week on the
s a m e2d a y so fe a c hr e l e v a n tw e e k .
Previous analyses of diary cards explored the 24-hour
period as a whole (using the mean of two 24-hour diaries) to
provide total “on”/“oﬀ”t i m e s[ 16]. In the current post-hoc
analyses, the 24-hour period was subdivided, with the 0.5-
hour periods grouped into diﬀerent time intervals, deﬁned
retrospectively as: nighttime, 10pm–8am; daytime, 8am–
10pm; early morning, 5am–10am; morning, 8am–1pm;
afternoon, 1pm–6pm; and evening, 6pm–10pm.
Diary card entries were used to assess the dura-
tion/proportion of sleep time, number of nighttime awaken-
ings, “oﬀ” and “on” periods, proportion of patients “on” on
waking,andtimespent“on”withouttroublesomedyskinesia
in both groups.
2.4. Statistical Analyses
2.4.1. Endpoints. Changes from baseline analyzed post-hoc
at week 24 last observation carried forward (LOCF) were:
the duration of sleep during the day, morning, afternoon,
evening, and nighttime; theamount of awake time spent
“on”, and “on” without troublesome dyskinesia, during the
day, morning, afternoon and evening; and the percentage
of awake time spent “on”, and “on” without troublesome
dyskinesia, during the night and early morning.
The proportion of patients with a decrease from baseline
inthenumberofawakeningspernightandtheproportionof
patients “on” on waking in the morning (according to both
diary days) at week 24 LOCF were also analyzed post-hoc.
2.4.2. Analyses. Patients were considered “on” on waking
at a visit if they were “on” on waking for both diary
days otherwise; they were considered “oﬀ”. Due to the lowParkinson’s Disease 3
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Table 1: Demographics and baseline characteristics of patients (intent-to-treat population).
Ropinirole prolonged release (n = 201) Placebo (n = 190)
Age, years 66.3 (9.17) 66.0 (9.74)
Women, n (%) 84 (42) 61 (32)
Age at onset of PD, years 57.6( 1 0 .53)
a 57.3( 1 0 .74)
b
Duration of PD, years 8.6( 4 .76)
a 8.6( 5 .15)
b
Duration of L-dopa treatment, years 6.5( 4 .45)
c 6.6( 4 .33)
d
L-dopa dose,mg/day 824 (424.4)
c 776 (357.3)
Total daily awake time spent “on”, hours 9.0 (2.75) 9.1 (2.69)
Amount of awake time spent “on”, hours
Daytime (8am–10pm) 7.9( 2 .24)
e 7.8( 2 .13)
f
Morning (8am–1pm) 3.0( 1 .06)
e 2.9( 0 .97)
f
Afternoon(1pm–6pm) 2.7( 0 .90)
e 2.7( 0 .87)
f
Evening (6pm–10pm) 2.2( 0 .93)
e 2.2( 0 .95)
f
Percentage awake time spent “on”
Nighttime (10pm–8am) 40.0( 2 5 .79)
e 39.9( 2 8 .49)
f
Early morning (5am–10am) 50.2( 2 5 .20)
e 47.6( 2 4 .99)
f
Patients “on” on waking in the morning, n (%)
g 28 (15)
d 24 (14)
h
Duration of sleep time, hours
Daytime (8am–10pm) 0.8( 0 .99)
e 0.9( 1 .07)
f
Nighttime (10pm–8am) 7.1( 1 .48)
e 7.1( 1 .31)
f
Patients with no awakenings/night, n (%)
g 110 (59)
d 86 (50)
h
an = 200; bn = 188; cn = 199; dn = 187; en = 190; fn = 175; gweek 0 data (two diary card days from the second week of the baseline period)), hn = 173.
All values are mean (SD) unless stated otherwise.
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Figure 2: aAdjusted mean change from baseline at week 24 LOCF
in the proportion of awake time spent “on” during the night and in
the early morning (intent-to-treat population).
proportion of patients waking “on” at baseline according
to this deﬁnition, a sensitivity analysis was also performed
whereby patients were considered “on” if they were “on” on
waking on either of the diary days. A nighttime awakening
was deﬁned as a period during the night (10pm–8am) in
which patients recorded themselves as “on” or ”oﬀ”( o n e
or more consecutive 0.5-hour periods awake, regardless of
state), preceded and succeeded by a recorded sleep time.
For assessments of the number of awakenings per night, the
maximum number of awakenings from the two diary days at
each study visit was used for analysis.
The intent-to-treat population (all patients who received
at least one dose of study medication and who had at
least one postbaseline eﬃcacy assessment) was used for all
analyses.Forcontinuousendpoints,baselinewastakenasthe
mean of the four 24-hour periods recorded between screen-
ing and baseline; however, for analyses of being “on” on wak-
ing,andnumberofnighttimeawakenings,baselinemeasure-
mentsutilizedonlythetwodiarycardsfromthesecondweek
(i.e., week 0 data) to ensure methodology was consistent
with that used for postbaseline data. All data for postbaseline
visits were calculated using the mean of the two diary days
completed before each visit. Changes from baseline to week
24 LOCF were analyzed for between-group diﬀerences using
an analysis of covariance (ANCOVA) model, adjusted for
countryandbaselinevalue;ifmodelassumptionsunderlying
the parametric analysis were not respected, a nonparametric
analysis (van Elteren test), adjusted for country, was utilized.
A logistic regression model, adjusting for country, was used
to analyze the proportion of patients with a decrease fromParkinson’s Disease 5
Placebo
(n = 175)
Ropinirole
prolonged release
(n = 190)
1.5
2
1
0.5
0
−0.5
A
d
j
u
s
t
e
d
a
m
e
a
n
(
S
E
)
c
h
a
n
g
e
f
r
o
m
b
a
s
e
l
i
n
e
i
n
t
h
e
a
m
o
u
n
t
o
f
a
w
a
k
e
t
i
m
e
“
o
n
”
(
h
o
u
r
s
)
AMTD 1.45
(95% CI: 0.88, 2.03)
P< . 0 00 0 1
(a)
Ropinirole prolonged release (n = 190)
Placebo (n = 175)
Afternoon
(1pm–6pm)
Evening
(6pm–10pm)
Morning
(8am–1pm)
0.6
0.8
0.4
0.2
0
−0.2
−0.4
A
d
j
u
s
t
e
d
a
m
e
a
n
(
S
E
)
c
h
a
n
g
e
f
r
o
m
b
a
s
e
l
i
n
e
i
n
t
h
e
a
m
o
u
n
t
o
f
a
w
a
k
e
t
i
m
e
“
o
n
”
(
h
o
u
r
s
)
AMTD, adjusted mean treatment diﬀerence; CI, conﬁdence interval;
LOCF, last observation carried forward; SE, standard error.
Adjusted a for country and baseline amount of awake time “on” (hours).
AMTD 0.59
(95% CI: 0.35, 0.84)
P<. 0001
AMTD 0.43
(95% CI: 0.18, 0.67)
P = .0007 AMTD 0.44
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Figure 3: aAdjusted mean change from baseline in theamount of
awake time spent “on” (hours) at week 24 LOCF (intent-to-treat
population) (a) during the daytime (8am–10pm); (b) during each
period of the daytime.
baseline in the number of awakenings per night, and the
proportion of patients “on” on waking in the morning, at
week 24 LOCF. Missing data were handled using LOCF
imputation.
3. Results
3.1. Patients. Baseline characteristics are presented in
Table 1. Diary card data were unavailable for 26/391 patients
at baseline (11 ropinirole prolonged release, 15 placebo),
and 24/391 patients at week 24 LOCF (11 ropinirole
prolonged release, 13 placebo). Therefore, analyses included
190 patients in the ropinirole prolonged release group and
175 patients in the placebo group. As reported previously
[16], 191/201 (95%) patients in the ropinirole prolonged
releasegroupand174/190(92%)intheplacebogrouphadL-
dopadosereduction;reinstatementofL-dopafollowingdose
reduction was required for 14/191 (7%) and 49/174 (28%)
patients, respectively. The reduction in L-dopa dose was
larger in the ropinirole prolonged release group than in the
placebo group (mean standard deviation (SD) change from
baseline −278 [193]mg/day versus −164 [164]mg/day).
3.2. Sleep Duration during the Night and Day. At baseline,
the mean (SD)amount of sleep time during the night and
day was similar for patients in both groups (Table 1). At
week 24 LOCF, the mean (SD) duration of sleep time during
the nighttime and daytime was 7.34 (1.47) and 0.9 (1.15)
hours for patients in the ropinirole prolonged release group,
and 7.22 (1.50) and 1.0 (1.24) hours in the placebo group,
respectively.
At night, sleep duration increased in both groups from
baseline to week 24 LOCF, and there was a nonsigniﬁcant
trend for a greater increase in the ropinirole prolonged
release group (adjusted mean treatment diﬀerence [AMTD],
0.16; 95% conﬁdence interval [CI]: −0.09, 0.41; P = 0.2041).
Both treatment groups had a small increase in sleep duration
(approximately 6-7 minutes) during the daytime but there
was no signiﬁcant diﬀerence between groups (P = 0.4205;
nonparametric van Elteren test). There were small changes
from baseline for individual periods of the day, which were
nonsigniﬁcant between treatments.
3.3. Nocturnal Awakenings. No signiﬁcant treatment eﬀect
was detected for the proportion of patients with a decrease
from baseline in the number of awakenings per night at
week 24 LOCF (odds ratio 1.43; 95% CI: 0.85, 2.39; P =
0.180), although a higher proportion of patients receiving
ropinirole prolonged release (25%; 46/187) had a decrease
compared with placebo (18%; 32/173). These relatively small
proportions may be due to a high proportion of patients
in each group (110/187 [59%] ropinirole prolonged release,
86/173 [50%] placebo) having no awakenings per night at
baseline (Table 1) according to the deﬁnition applied. An
analysis excluding the patients with no baseline nocturnal
awakenings showed a larger treatment eﬀect, with a higher
proportion of patients receiving ropinirole prolonged release
(60%; 46/77) having a decrease from baseline in the number
of awakenings per night at week 24 LOCF compared
with placebo (37%; 32/87). This diﬀerence was signiﬁcant
(adjusted [for country] odds ratio 2.46; 95% CI 1.29, 4.68;
P = 0.0060).6 Parkinson’s Disease
3.4. Motor Symptom Control
3.4.1. Awake Time Spent “on” during the Nighttime and Early
Morning. At week 24 LOCF, mean (SD) percentage of awake
time spent “on” was: 57.0% (32.22) at nighttime and 64.5%
(29.27) in the early morning for the ropinirole prolonged
release group, and 43.6% (37.44) at nighttime and 53.7%
(31.31) in the early morning for the placebo group. Patients
receiving ropinirole prolonged release had a signiﬁcantly
greater increase in the percentage of awake time spent “on”
both during the nighttime (AMTD 12.7%; 95% CI: 5.94,
19.41; P = 0.0002) and early morning (AMTD 9.1%;
95% CI: 3.31, 14.84; P = 0.0021), compared with patients
receiving placebo (Figure 2). There were also statistically sig-
niﬁcant treatment beneﬁts in favor of ropinirole prolonged
release for the percentage of awake time spent “on” without
troublesome dyskinesia, at week 24 LOCF for the nighttime
and early morning. Compared with placebo, patients who
received ropinirole prolonged release had, on average, 11%
more awake time spent “on” without troublesome dyskinesia
during the night (AMTD: 10.94; 95% CI: 4.21, 17.66; P =
0.0015) and 8% more during the early morning (AMTD:
8.10; 95% CI: 2.28, 13.93; P = 0.0065).
3.4.2. Awake Time Spent “on” during the Daytime. At base-
line, the mean (SD)amount of awake time spent “on” during
the daytime (8am–10pm) was similar (approximately 8
hours) for patients receiving ropinirole prolonged release
and placebo (Table 1).
At week 24 LOCF, the mean (SD)amount of awake time
spent “on” during the daytime was 9.4 (3.09) hours for
patients receiving ropinirole prolonged release and 7.9 (3.16)
hours for patients receiving placebo.
Therewasasigniﬁcantlygreaterimprovementfrombase-
line to week 24 LOCF in “on” time while awake during the
daytime for patients receiving ropinirole prolonged release
versus placebo (AMTD: 1.45; 95% CI: 0.88, 2.03; P<0.0001;
Figure 3(a)). For each of the daily time periods considered,
there were statistically signiﬁcant treatment beneﬁts in favor
of ropinirole prolonged release for the change from baseline
in theamount of awake time spent “on”, at week 24 LOCF
(Figure 3(b)).
There were also statistically signiﬁcant treatment beneﬁts
in favor of ropinirole prolonged release for time spent “on”
without troublesome dyskinesia, at week 24 LOCF for the
daytime (AMTD: 1.29; 95% CI: 0.71, 1.87; P<0.0001), and
for each of the diﬀerent daily periods considered: morning
(AMTD: 0.54; 95% CI: 0.29, 0.78; P<0.0001), afternoon
(AMTD: 0.40; 95% CI: 0.15, 0.64; P = 0.0016), and evening
(AMTD: 0.39; 95% CI: 0.17, 0.60; P = 0.0004).
3.4.3. Probability of Waking “on”. Despite the stringent deﬁ-
nition applied for being “on” (“on” on waking for both diary
days), over one-third (37%; 70/190) of patients receiving
ropinirole prolonged release awoke “on” at week 24 LOCF,
compared with 26% (46/177) in the placebo group. For a
patient receiving ropinirole prolonged release, the adjusted
(for country) odds of being “on” on waking in the morning
were 1.65 (95% CI: 1.05, 2.59) times higher than for a
patient receiving placebo, and this diﬀerence was signiﬁcant
(P = 0.029). A sensitivity analysis with a less stringent
deﬁnition (“on” on waking on either day) showed that a
higher proportion of patients in both groups awoke “on”
at week 24 LOCF (52% [98/190] for ropinirole prolonged
release and 36% [63/177] for placebo) and this supported
the original analysis (adjusted odds of being “on” on waking
in the morning, 1.94 [95% CI: 1.27, 2.96]; P = 0.002).
4. Discussion
Ropinirole prolonged release is a non-ergoline D2/D3
dopamine agonist which has been shown to be eﬀective
in PD not only when used as monotherapy [17], but also
when used as an adjunct to L-dopa in advanced PD [16].
In addition to improvement in motor ﬂuctuations in this
patient population, treatment with ropinirole prolonged
release has been shown to permit a reduction in L-dopa dose
(approximately 30% [16]) and this may help toameliorate
the dyskinesia that can emerge upon initiation of adjunctive
therapy. Initial analysis of the EASE-PD Adjunct study
showed that once-daily ropinirole prolonged release as an
adjunct to L-dopa increased “on” time over a 24-hour period
in patients with advanced PD, and also reduced nocturnal
symptoms (as measured by the PDSS) [16]. Data from
this study have also shown that beneﬁts are seen as early
as 2 weeks after treatment initiation [18]. The post-hoc
analyses of the diary card data from EASE-PD reported
here show that signiﬁcant improvements in “on” time were
experienced during the nighttime and in all periods of
the day by patients receiving ropinirole prolonged release,
compared with placebo, despite only once-daily dosing.
This was not due to a decrease in overall sleep duration,
which remained similar between treatment groups. Patients
receivingropiniroleprolongedreleasealsohadasigniﬁcantly
higher probability of being “on” on waking relative to
those receiving placebo. These data conﬁrm that once-daily
treatment with ropinirole prolonged release is capable of
providing consistent symptomatic beneﬁts throughout the
whole day.
To our knowledge, this is the ﬁrst analysis in which
the 24-hour dose period has been subdivided into speciﬁc
periods to assess the continued eﬀect of prolonged-release
dopamineagonisttreatment.Thisallowedthedetermination
of whether symptomatic beneﬁts were consistently observed
across diﬀerent periods of the day and night and enabled
the study of quantitative aspects of sleep not captured by the
PDSS.
No signiﬁcant treatment diﬀerences were observed in
change in nighttime or daytime sleep duration. Overall,
nighttime and daytime sleep increased slightly during the
study, but changes were small and similar for both groups.
The data from this study suggest that ropinirole prolonged
release neither signiﬁcantly reduces nighttime sleep nor
increases sleep time during the day in patients with advanced
PD. This latter point is consistent with previously reportedParkinson’s Disease 7
nonsigniﬁcant diﬀerences in change in Epworth Sleepiness
Scale scores from this study [16].
In the placebo group, 18% of patients experienced a
decrease in the number of awakenings per night from
baseline, compared with 25% in the ropinirole prolonged
release group; this was not statistically signiﬁcant, possibly
because a high proportion of patients in both groups
(59% ropinirole prolonged release, 50% placebo) had no
awakenings at night at baseline (and therefore could not
experience a reduction). This position is supported by the
results of a further analysis which excluded those patients
with no awakenings at night at baseline; this showed that a
signiﬁcantly higher proportion of patients in the ropinirole
prolonged release group (60%) versus the placebo group
(37%) experienced a decrease in the number of awakenings
from baseline.
Over 24 weeks, patients receiving ropinirole prolonged
release gained almost 1.5 hours more awake time “on”
duringtheday(8am–10pm)thanpatientsreceivingplacebo.
A signiﬁcant beneﬁt for ropinirole prolonged release was
seen during the morning, and these eﬀects were maintained
throughout the afternoon and evening. Results for awake
time spent “on” without troublesome dyskinesia were sup-
portive of beneﬁts across the night and daytime periods,
consistent with results reported for the 24-hour period as a
whole [16].
As reported in the main analysis, ropinirole prolonged
release was well tolerated in the patient population studied,
and adverse events reported were typical for a dopamine
agonist [16]. However, when considering treatments with
these medications, including ropinirole prolonged release,
it is important to be mindful of the precautions associated
with this class, including impulse control disorders and
episodes of sudden onset of sleep [19], and take these into
consideration along with the potential beneﬁts.
Self-reported diary cards are important tools in clinical
research [20], as they provide an accurate reﬂection of
clinical status over a period of time and can generate a
lot of information in a simple format. However, there may
be limitations associated with the data collected. Responses
are subjective, and therefore the validity of the data relies
on patients accurately completing their diaries, which may,
in turn, be inﬂuenced by the patient’s mental status; for
example, decreasing memory over time may aﬀect patients’
ability to complete diary cards in a timely manner. With no
indication of the timing of diary completion in this study,
this parameter could not be assessed. Another potential
limitation is that due to the way the diary is structured, data
are collected in 30-minute increments. Thus, results may be
insensitive to exact timing of events, for example, for falling
asleeporwakingup:deﬁnedtimeperiodsmaynotaccurately
reﬂect each individual patient’s sleep patterns. Measuring
nighttime awakenings in this way is likely to be particularly
insensitive; use of polysomnography, actigraphy or even
subjective reports would most probably have identiﬁed
many more awakenings than were captured by the diary
card approach. To our knowledge, no such studies have
been conducted on a large scale with ropinirole prolonged
release, although some ﬁndings have been reported in a
subset of patients from a small, unblinded trial [21]. In
addition, on diary days, the need to complete the diary
card in an accurate and timely fashion may cause patients
undue worry, which may aﬀect their usual routine. Finally,
it must be acknowledged that the analyses presented here
were performed post-hoc, and therefore a degree of caution
should be exercised when interpreting the ﬁndings. Despite
methodological diﬀerences, the results of these post-hoc
analyses are in line with those from the main analysis of the
trial [16].
5. Conclusion
Although post-hoc, this novel analysis of diary card data
provides additional support that once-daily ropinirole pro-
longed release as an adjunctive therapy may help to provide
24-hour symptom control in patients with advanced PD not
optimally controlled by L-dopa. Patient beneﬁts are apparent
during the day and night, and immediately upon waking.
As the population of patients included in this controlled
study appears to be representative of patients with advanced
stage PD seen in daily practice, the results can be considered
relevant and applicable to a real-life setting.
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